Followers | 237 |
Posts | 10817 |
Boards Moderated | 0 |
Alias Born | 07/17/2006 |
Tuesday, June 29, 2021 1:27:21 PM
I like to keep up in medical science..but I admit I was not up the pathophysiology and the impact that AEMD's "Hemo Purifier"could have on clinical medicine...
There is an enormous gap between medical science and clinical medicine.
Clinicians. The doctors you see are largely retro and make no pretense in terms of keeping up with medical science. In fact the Hippocratic Oath inveighs against treatments that are novel...The oath says "Experiment is Perilous". Doctors entering clinical practice are cautioned not to be the first in their territory to try new treatments. Mal Practice forces clinicians to practice "defensive medicine"..Not only does this raise the cost of medicine some 40%...but also retards medical progress but costs lives..The only winners is the Med-Mal industry...
AEMD's device is a method of preventing viruses and cancers of spreading by using the blood stream...Both Viruses and cancer cells operate by using their DNA and RNA to alter the host DNA and RNA to produce the viral or the cancers own genetic code to produce viruses or cancer cells. The process is complicated by the fact that the programing genetic sequences must traverse the cell wall of the infected host cell. then enter the bloodstream, then penetrate the cells the cancer or virus they wish to infect.. This is a perilous journey because the genetic material must obey the laws of physics and this means the transported genetic material must present present polar molecules to polar surfaces and non polar molecules to non polar surfaces..
The viral or cancer cell need help and they get it from nano sized bubbles in the host's cytoplasm called exosomes.. the Viruses pack up their genetic material for the trip outside the cell,,into the blood stream and into the cell they wish to infect..These tiny bubbles are are optimally designed to be transport carriers and without them the virus or the cancer cell can not spread. Because the cancer cells or viruses would be destroyed in the blood stream without the protection of the exosomes..
What AEMD's hemo purifier does is it stops "destroys" the exosomes in the bloodstream.. This leads to the viruses and cancer to be vulnerable to the bodies immune and inflammatory systems..This should work with all viruses and cancers .
THAT IS WHY THIS IS VERY BIG DEAL...
":>) JL
Recent AEMD News
- Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update • PR Newswire (US) • 06/27/2024 08:15:00 PM
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024 • PR Newswire (US) • 06/21/2024 12:01:00 PM
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 06/18/2024 12:01:00 PM
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies • PR Newswire (US) • 06/03/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 05:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:28 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/17/2024 04:15:21 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/16/2024 08:05:23 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/15/2024 01:27:15 PM
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering • PR Newswire (US) • 05/15/2024 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/13/2024 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:01:40 PM
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma • PR Newswire (US) • 05/10/2024 12:01:00 PM
- Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices • PR Newswire (US) • 02/21/2024 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:41 PM
- Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024 • PR Newswire (US) • 02/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:04:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:02:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:01:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 12:49:31 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM